Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats.
Effects of a new lipophilic L-type calcium channel blocker, azelnidipine, on the expression of molecular components of the renin-angiotensin-aldosterone system (RAAS) were assessed. Male Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of diabetes with hypertension, and their lean littermates, Long-Evans Tokushima Otsuka (LETO) rats, were treated with azelnidipine for 2 weeks. The renal cortical mineralocorticoid receptor mRNA in OLETF was higher than in LETO, but was suppressed (P<0.05) by azelnidipine. Renal cortical angiotensin-converting enzyme mRNA of OLETF was lower than that of LETO rats, and it was further suppressed by azelnidipine (P<0.05). Azelnidipine can down-regulate the gene expression of molecular components of RAAS.
Nakamura
Tetsuya
T
Clinical Investigation and Research Unit, Gunma University Hospital, Japan. nakamurt@showa.gunma-u.ac.jp
Saito
Yuichiro
Y
Saito
Tomoko
T
Kurabayashi
Masahiko
M
D000818:Animals; D001013:Aorta, Thoracic / Q000201:enzymology / Q000378:metabolism; D001383:Azetidinecarboxylic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000201:enzymology* / Q000378:metabolism; D004095:Dihydropyridines / Q000494:pharmacology*; D015536:Down-Regulation; D006321:Heart / Q000187:drug effects; D006973:Hypertension / Q000150:complications / Q000201:enzymology* / Q000378:metabolism; D007672:Kidney Cortex / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D008297:Male; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D007703:Peptidyl-Dipeptidase A / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D011919:Rats, Inbred Strains; D018161:Receptors, Mineralocorticoid / Q000096:biosynthesis*; D012084:Renin-Angiotensin System / Q000187:drug effects
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D012333:RNA, Messenger; D018161:Receptors, Mineralocorticoid; D001383:Azetidinecarboxylic Acid; D007703:Peptidyl-Dipeptidase A; C061679:azelnidipine